Prior Authorizations and Step Therapy Impact to Patients in Specialty Markets
The analytics used in this publication were originally commissioned by the Pharmaceutical Research and Manufacturers of America (PhRMA).
Fact Sheet
Jun 24, 2020

Utilization management restrictions are common across a variety of therapeutic areas, but treatments for managing rheumatoid arthritis (RA) and multiple sclerosis (MS) are two examples of areas subject to particularly heavy control. This fact sheet, with analytics commissioned by Pharmaceutical Research and Manufacturers of America (PhRMA), highlights formulary restrictions, payer restrictions, cost-sharing assistance utilization rates and other analyses from IQVIA's Market Access Strategy Consulting team.

You may also be interested in